Peripheral F2‐isoprostanes and F4‐neuroprostanes are not increased in Alzheimer's disease
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Quantitative biomarkers of oxidative damage, such as the F 2‐isoprostanes (IsoPs) and F 4‐neuroprostanes (F 4‐NeuroPs), may be useful in assessing progression and response to therapeutics in patients with Alzheimer's disease. F 2‐IsoPs and F 4‐NeuroPs are reproducibly increased in brain and cerebrospinal fluid of Alzheimer's disease patients; however, results in blood and urine have been conflicting. We tested the hypothesis that F 2‐IsoPs and F 4‐NeuroPs in plasma or urine quantitatively reflect oxidative damage to the central nervous system. Our results showed that urine levels of F 2‐IsoPs or their major metabolite were not significantly different between 56 Alzheimer's disease patients and 34 controls. In addition, urine and cerebrospinal fluid F 2‐IsoP levels in 32 Alzheimer's disease patients did not correlate. Supporting these conclusions, elevated rat cerebral F 2‐IsoPs and F 4‐NeuroPs after systemic exposure to kainic acid were not associated with a significant change in their plasma or urine levels. These results show that plasma and urine F 2‐IsoPs and F 4‐NeuroPs do not accurately reflect central nervous system levels of these biomarkers and are not reproducibly elevated in body fluids outside of central nervous system in Alzheimer's disease patients. These results should guide the organization of clinical trials now being planned for patients with Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405 · cited 1×
“These studies have used several biomarkers including F2-isoprostanes (F2-IsoPs), quantitative in vivo biomarkers of free radical damage to arachidonic acid.(5,6) Moreover, F2-IsoP levels are increased in cerebrospinal fluid (CSF) obtained postmortem from the lateral ventricle of definite AD patients with advanced deme…”
Method
Cited by
Halliwell, B., & Whiteman, M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705776 · Cited by 2,238
Biomarkers of Oxidative Damage in Human Disease
Dalle-Donne, I., Rossi, R., Colombo, R., Giustarini, D., & Milzani, A. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.061408 · Cited by 1,703
The role of reactive oxygen and antioxidant species in periodontal tissue destruction
Chapple, I. L. C., & Matthews, J. B. (2007) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00178.x · Cited by 936
Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview
Mariani, E., Polidori, M. C., Cherubini, A., & Mecocci, P. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.04.023 · Cited by 680
Evidence of increased oxidative damage in subjects with mild cognitive impairment
Keller, J. N., Schmitt, F. A., Scheff, S. W., Ding, Q., Chen, Q., Butterfield, D. A., & Markesbery, W. R. (2005) · Neurology · doi:10.1212/01.wnl.0000156156.13641.ba · Cited by 539
Metadata
- Authors
- Montine, T. J., Quinn, J. F., Milatovic, D., Silbert, L. C., Dang, T., Sanchez, S., Terry, E., Roberts, L. J., Kaye, J. A., & Morrow, J. D.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2002-07-23
- Volume
- 52
- Issue
- 2
- Pages
- 175-179
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2055021833
- Cited by
- 155
- References
- 1
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peripheral F2‐isoprostanes and F4‐neuroprostanes are not increased in Alzheimer's disease. https://app.cochat.ai/papers/10.1002/ana.10272
- The paper
- Montine, T. J., Quinn, J. F., Milatovic, D., Silbert, L. C., Dang, T., Sanchez, S., Terry, E., Roberts, L. J., Kaye, J. A., & Morrow, J. D. (2002). Peripheral F2‐isoprostanes and F4‐neuroprostanes are not increased in Alzheimer's disease. Annals of Neurology. https://doi.org/10.1002/ana.10272
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.